Ramanomics

Ramanomics is an Oxford University spinout founded in 2022 to tackle one of the most consequential diagnostic gaps in modern medicine: the inability to rapidly identify the pathogen causing an infection and understand its resistance profile before prescribing antibiotics. Under current standard-of-care, culture-based methods take up to three days to return results, during which patients receive empirical antibiotic treatment that may be inappropriate and contributes to the global antimicrobial resistance crisis. Ramanomics was created to compress that timeline to under three hours — without requiring a culture at all.

The company's platform combines Raman spectroscopy with machine learning to identify bacteria and fungi directly from clinical samples and generate an antimicrobial resistance profile in a single workflow. Raman spectroscopy reads the biochemical fingerprint of individual microbial cells, while Ramanomics' proprietary software interprets this data at speed and with clinical-grade accuracy. The technology has particular relevance in acute settings where sepsis or severe respiratory infection is suspected and every hour of delayed appropriate treatment carries mortality risk.

Ramanomics has received grant funding from Innovate UK, was named by the UK Government as one of the country's most innovative young companies, and raised £1.8 million in 2025 to accelerate its platform towards clinical deployment. The company is a member of the Oxford Centre for Innovation and has partnered with leading academic and clinical institutions to validate its approach.